Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 2/20 | 0.61 |
| ▸ | PPARD | Q03181 | 2/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.61 |
| ▸ | SLC10A6 | Q3KNW5 | 2/20 | 0.59 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.59 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.59 |
| ▸ | GPR27 | Q9NS67 | 5/20 | 0.57 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.57 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.56 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 3/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | CPT2 | P23786 | 1/20 | 0.52 |
| ▸ | CPT1A | P50416 | 1/20 | 0.52 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862400 | 0.90 | SLC10A6 (0.71) | SLC10A6SLC10A2SLC10A1GPR27AVPR2 | |
| SCHEMBL6863831 | 0.89 | KMT2A (0.63) | SLC10A6SLC10A2SLC10A1GPR27AVPR2 | |
| SCHEMBL6860624 | 0.87 | SLC10A6 (0.64) | SLC10A6SLC10A2SLC10A1GPR27AVPR2 | |
| SCHEMBL1138705 | 0.87 | SLC10A6 (0.63) | SLC10A6SLC10A2SLC10A1GPR27AVPR2 | |
| SCHEMBL6860636 | 0.86 | LMNA (0.64) | CCR9SLC10A6SLC10A2SLC10A1GPR27 | |
| SCHEMBL6862376 | 0.86 | SLC10A6 (0.76) | CCR9SLC10A6SLC10A2SLC10A1GPR27 | |
| SCHEMBL6862206 | 0.84 | SLC10A6 (0.65) | SLC10A6SLC10A2SLC10A1GPR27AVPR2 | |
| SCHEMBL5125728 | 0.84 | SLC10A6 (0.61) | CCR9SLC10A6SLC10A2SLC10A1GPR27 | |
| SCHEMBL6860504 | 0.84 | SLC10A6 (0.59) | CCR9SLC10A6SLC10A2SLC10A1GPR27 | |
| SCHEMBL6860323 | 0.84 | SLC10A6 (0.59) | SLC10A6SLC10A2SLC10A1GPR27AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | claimed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | claimed |
| CN-1213019-C | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-08-03 | — | — | CN | disclosed |
| US-6790866-B2 | SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | OHUCHIDA SHUICHI (JP) | 2003-03-27 | — | — | US | disclosed |
| CN-1247529-A | Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2000-03-15 | — | — | CN | disclosed |
| EP-0947500-A1 | SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060460-A1 | Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity | CNR1, HCAR1, HCAR2 | CCR9 1142/4885PPARG 253/4885PPARD 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.